Lukáš Smolej

Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial

Andrew D. Zelenetz, Jacqueline C. Barrientos, Jennifer R Brown et al. · The Lancet Oncology · 2017 · 247 citations · Full text

Hematological Malignancy, Lymphoid Neoplasia, Oncology +11

Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network

Chan Y. Cheah, Anupkumar George, Eva Giné et al. · Annals of Oncology · 2013 · 130 citations · Full text

Prognostic Factors, Neuro-oncology, Lymphoid Neoplasia +4

Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia

William G. Wierda, Thomas J. Kipps, Jan Dürig et al. · Blood · 2011 · 120 citations · Full text

Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study

Marinus H. J. van Oers, Kazimierz Kuliczkowski, Lukáš Smolej et al. · The Lancet Oncology · 2015 · 112 citations

Hematological Malignancy, Lymphoid Neoplasia, Autoimmune Disease +11

Management of chronic lymphocytic leukemia (CLL) in the elderly: a position paper from an international Society of Geriatric Oncology (SIOG) Task Force

R. Stauder, Barbara Eichhorst, Marije E. Hamaker et al. · Annals of Oncology · 2016 · 104 citations

Hematological Malignancy, Lymphoid Neoplasia, Geriatric Oncology +11